Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2016 3
2017 1
2018 3
2019 5
2020 2
2021 1
2023 1
2024 1
2025 3
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 2
Differentiation of Murine C2C12 Myoblasts Strongly Reduces the Effects of Myostatin on Intracellular Signaling.
Lautaoja JH, Pekkala S, Pasternack A, Laitinen M, Ritvos O, Hulmi JJ. Lautaoja JH, et al. Among authors: hulmi jj. Biomolecules. 2020 Apr 30;10(5):695. doi: 10.3390/biom10050695. Biomolecules. 2020. PMID: 32365803 Free PMC article.
The effects of tumorkines were analyzed after coculture of C2C12 and colon cancer-C26 cells. The effects of myostatin on canonical and noncanonical signaling were strongly reduced in C2C12 cells after differentiation. ...
The effects of tumorkines were analyzed after coculture of C2C12 and colon cancer-C26 cells. The effects of myostatin on canonical an …
Blocking Activin Receptor Ligands Is Not Sufficient to Rescue Cancer-Associated Gut Microbiota-A Role for Gut Microbial Flagellin in Colorectal Cancer and Cachexia?
Pekkala S, Keskitalo A, Kettunen E, Lensu S, Nykänen N, Kuopio T, Ritvos O, Hentilä J, Nissinen TA, Hulmi JJ. Pekkala S, et al. Among authors: hulmi jj. Cancers (Basel). 2019 Nov 15;11(11):1799. doi: 10.3390/cancers11111799. Cancers (Basel). 2019. PMID: 31731747 Free PMC article.
Colorectal cancer (CRC) and cachexia are associated with the gut microbiota and microbial surface molecules. ...Cancer-associated gut microbiota could not be rescued by blocking ACVR ligands....
Colorectal cancer (CRC) and cachexia are associated with the gut microbiota and microbial surface molecules. ...Cancer-associa …
Muscle and serum metabolomes are dysregulated in colon-26 tumor-bearing mice despite amelioration of cachexia with activin receptor type 2B ligand blockade.
Lautaoja JH, Lalowski M, Nissinen TA, Hentilä J, Shi Y, Ritvos O, Cheng S, Hulmi JJ. Lautaoja JH, et al. Among authors: hulmi jj. Am J Physiol Endocrinol Metab. 2019 May 1;316(5):E852-E865. doi: 10.1152/ajpendo.00526.2018. Epub 2019 Mar 12. Am J Physiol Endocrinol Metab. 2019. PMID: 30860875 Free article.
The purpose of this study was to unravel the underlying physiology and novel cachexia biomarkers by use of the colon-26 (C26) carcinoma model of cancer cachexia. Male BALB/c mice were subcutaneously inoculated with C26 cancer cells or vehicle control. ...However, th …
The purpose of this study was to unravel the underlying physiology and novel cachexia biomarkers by use of the colon-26 (C26) carcinoma mode …
Systemic Blockade of ACVR2B Ligands Protects Myocardium from Acute Ischemia-Reperfusion Injury.
Magga J, Vainio L, Kilpiö T, Hulmi JJ, Taponen S, Lin R, Räsänen M, Szabó Z, Gao E, Rahtu-Korpela L, Alakoski T, Ulvila J, Laitinen M, Pasternack A, Koch WJ, Alitalo K, Kivelä R, Ritvos O, Kerkelä R. Magga J, et al. Among authors: hulmi jj. Mol Ther. 2019 Mar 6;27(3):600-610. doi: 10.1016/j.ymthe.2019.01.013. Epub 2019 Jan 24. Mol Ther. 2019. PMID: 30765322 Free PMC article.
Activin Receptor Ligand Blocking and Cancer Have Distinct Effects on Protein and Redox Homeostasis in Skeletal Muscle and Liver.
Hentilä J, Nissinen TA, Korkmaz A, Lensu S, Silvennoinen M, Pasternack A, Ritvos O, Atalay M, Hulmi JJ. Hentilä J, et al. Among authors: hulmi jj. Front Physiol. 2019 Jan 18;9:1917. doi: 10.3389/fphys.2018.01917. eCollection 2018. Front Physiol. 2019. PMID: 30713500 Free PMC article.
Muscle wasting in cancer cachexia can be alleviated by blocking activin receptor type 2 (ACVR2) ligands through changes in protein synthesis/degradation. ...Muscle GSH and many of the altered UPR indicators correlated with tumor mass, fat mass and body mass loss. In conclu …
Muscle wasting in cancer cachexia can be alleviated by blocking activin receptor type 2 (ACVR2) ligands through changes in protein sy …
Moderate exercise in mice improves cancer plus chemotherapy-induced muscle wasting and mitochondrial alterations.
Ballarò R, Beltrà M, De Lucia S, Pin F, Ranjbar K, Hulmi JJ, Costelli P, Penna F. Ballarò R, et al. Among authors: hulmi jj. FASEB J. 2019 Apr;33(4):5482-5494. doi: 10.1096/fj.201801862R. Epub 2019 Jan 17. FASEB J. 2019. PMID: 30653354
In summary, chemotherapy further impinges on cancer-induced alterations, worsening muscle wasting. An ideal multifactorial and early intervention to prevent cancer cachexia could take advantage of exercise, improving patient's energy metabolism, mobility, and qualit …
In summary, chemotherapy further impinges on cancer-induced alterations, worsening muscle wasting. An ideal multifactorial and early …
Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses.
Nissinen TA, Hentilä J, Penna F, Lampinen A, Lautaoja JH, Fachada V, Holopainen T, Ritvos O, Kivelä R, Hulmi JJ. Nissinen TA, et al. Among authors: hulmi jj. J Cachexia Sarcopenia Muscle. 2018 Jun;9(3):514-529. doi: 10.1002/jcsm.12310. Epub 2018 May 2. J Cachexia Sarcopenia Muscle. 2018. PMID: 29722201 Free PMC article.
BACKGROUND: Cancer cachexia increases morbidity and mortality, and blocking of activin receptor ligands has improved survival in experimental cancer. ...The potential roles of muscle and non-muscle tissues in cancer cachexia were investigated in order to unde …
BACKGROUND: Cancer cachexia increases morbidity and mortality, and blocking of activin receptor ligands has improved survival in expe …
Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle.
Hulmi JJ, Nissinen TA, Räsänen M, Degerman J, Lautaoja JH, Hemanthakumar KA, Backman JT, Ritvos O, Silvennoinen M, Kivelä R. Hulmi JJ, et al. J Cachexia Sarcopenia Muscle. 2018 Apr;9(2):417-432. doi: 10.1002/jcsm.12265. Epub 2017 Dec 11. J Cachexia Sarcopenia Muscle. 2018. PMID: 29230965 Free PMC article.
BACKGROUND: Toxicity of chemotherapy on skeletal muscles and the heart may significantly contribute to cancer cachexia, mortality, and decreased quality of life. Doxorubicin (DOX) is an effective cytostatic agent, which unfortunately has toxic effects on many healthy tissu …
BACKGROUND: Toxicity of chemotherapy on skeletal muscles and the heart may significantly contribute to cancer cachexia, mortality, an …
VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection.
Räsänen M, Degerman J, Nissinen TA, Miinalainen I, Kerkelä R, Siltanen A, Backman JT, Mervaala E, Hulmi JJ, Kivelä R, Alitalo K. Räsänen M, et al. Among authors: hulmi jj. Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):13144-13149. doi: 10.1073/pnas.1616168113. Epub 2016 Oct 31. Proc Natl Acad Sci U S A. 2016. PMID: 27799559 Free PMC article.
Congestive heart failure is one of the leading causes of disability in long-term survivors of cancer. The anthracycline antibiotic doxorubicin (DOX) is used to treat a variety of cancers, but its utility is limited by its cumulative cardiotoxicity. As advances in …
Congestive heart failure is one of the leading causes of disability in long-term survivors of cancer. The anthracycline antibiotic do …
Systemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes.
Nissinen TA, Degerman J, Räsänen M, Poikonen AR, Koskinen S, Mervaala E, Pasternack A, Ritvos O, Kivelä R, Hulmi JJ. Nissinen TA, et al. Among authors: hulmi jj. Sci Rep. 2016 Sep 26;6:32695. doi: 10.1038/srep32695. Sci Rep. 2016. PMID: 27666826 Free PMC article.
These results demonstrate that blocking ACVR2B signalling may be a promising strategy to counteract chemotherapy-induced muscle wasting without damage to skeletal muscle oxidative capacity or cancer treatment....
These results demonstrate that blocking ACVR2B signalling may be a promising strategy to counteract chemotherapy-induced muscle wasting with …
23 results